EGFR and non-small cell lung carcinoma: Zhang et al. (8) provided clinical evidence supporting osimertinib’s efficacy in NSCLC patients with rare EGFR mutations (including G719X, L861G, and S768I), achieving a mPFS of 8.2 months.